PMID- 20857521
OWN - NLM
STAT- MEDLINE
DCOM- 20110128
LR  - 20211020
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 16
IP  - 36
DP  - 2010 Sep 28
TI  - Recent standardization of treatment strategy for pancreatic neuroendocrine 
      tumors.
PG  - 4519-25
AB  - Recent advances in localization techniques, such as the selective arterial 
      secretagogue injection test (SASI test) and somatostatin receptor scintigraphy 
      have promoted curative resection surgery for patients with pancreatic 
      neuroendocrine tumors (PNET). For patients with sporadic functioning PNET, 
      curative resection surgery has been established by localization with the SASI 
      test using secretin or calcium. For curative resection of functioning PNET 
      associated with multiple endocrine neoplasia type 1 (MEN 1) which are usually 
      multiple and sometimes numerous, resection surgery of the pancreas and/or the 
      duodenum has to be performed based on localization by the SASI test. As resection 
      surgery of PNET has increased, several important pathological features of PNET 
      have been revealed. For example, in patients with Zollinger-Ellison syndrome 
      (ZES), duodenal gastrinoma has been detected more frequently than pancreatic 
      gastrinoma, and in patients with MEN 1 and ZES, gastrinomas have been located 
      mostly in the duodenum, and pancreatic gastrinoma has been found to co-exist in 
      13% of patients. Nonfunctioning PNET in patients with MEN 1 becomes metastatic to 
      the liver when it is more than 1 cm in diameter and should be resected after 
      careful observation. The most important prognostic factor in patients with PNET 
      is the development of hepatic metastases. The treatment strategy for hepatic 
      metastases of PNET has not been established and aggressive resection with 
      chemotherapy and trans-arterial chemoembolization have been performed with 
      significant benefit. The usefulness of octreotide treatment and other molecular 
      targeting agents are currently being assessed.
FAU - Imamura, Masayuki
AU  - Imamura M
AD  - Department of Surgey, Kansai Denryoku Hospital, 2-1-7, Fukushima, Fukushima-Ku, 
      Osaka 553-0003, Japan. imamura.masayuki@c4.kepco.co.jp
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Gastrins)
RN  - 1393-25-5 (Secretin)
SB  - IM
MH  - Animals
MH  - Diagnosis, Differential
MH  - Gastrins/blood
MH  - Humans
MH  - Liver Neoplasms/secondary
MH  - Male
MH  - Multiple Endocrine Neoplasia Type 1/pathology/surgery
MH  - Neuroendocrine Tumors/epidemiology/pathology/physiopathology/*therapy
MH  - Pancreatic Neoplasms/epidemiology/pathology/physiopathology/*therapy
MH  - Secretin
MH  - Zollinger-Ellison Syndrome/pathology/surgery
PMC - PMC2945482
EDAT- 2010/09/22 06:00
MHDA- 2011/02/01 06:00
PMCR- 2010/09/28
CRDT- 2010/09/22 06:00
PHST- 2010/09/22 06:00 [entrez]
PHST- 2010/09/22 06:00 [pubmed]
PHST- 2011/02/01 06:00 [medline]
PHST- 2010/09/28 00:00 [pmc-release]
AID - 10.3748/wjg.v16.i36.4519 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2010 Sep 28;16(36):4519-25. doi: 10.3748/wjg.v16.i36.4519.